TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Insider Sells $34,172.46 in Stock

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) insider Richard Marshak sold 6,597 shares of the company’s stock in a transaction on Monday, May 19th. The shares were sold at an average price of $5.18, for a total value of $34,172.46. Following the transaction, the insider now directly owns 69,101 shares in the company, valued at $357,943.18. This trade represents a 8.71% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

TriSalus Life Sciences Trading Up 3.9%

NASDAQ TLSI opened at $5.56 on Friday. The company has a market capitalization of $179.43 million, a PE ratio of -2.23 and a beta of 0.50. The stock has a 50-day simple moving average of $5.42 and a 200 day simple moving average of $5.04. TriSalus Life Sciences, Inc. has a 12 month low of $3.50 and a 12 month high of $9.00.

TriSalus Life Sciences (NASDAQ:TLSI) last announced its quarterly earnings results on Thursday, May 15th. The company reported ($0.33) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.13). The company had revenue of $9.17 million for the quarter, compared to analyst estimates of $9.04 million. During the same quarter last year, the company earned ($0.60) EPS. As a group, sell-side analysts predict that TriSalus Life Sciences, Inc. will post -1.55 earnings per share for the current fiscal year.

Hedge Funds Weigh In On TriSalus Life Sciences

A number of hedge funds and other institutional investors have recently made changes to their positions in TLSI. Charles Schwab Investment Management Inc. bought a new position in shares of TriSalus Life Sciences during the first quarter worth $55,000. Renaissance Technologies LLC acquired a new position in TriSalus Life Sciences in the fourth quarter valued at about $67,000. Connective Capital Management LLC acquired a new position in TriSalus Life Sciences in the fourth quarter valued at about $140,000. Northern Trust Corp grew its stake in TriSalus Life Sciences by 22.7% in the fourth quarter. Northern Trust Corp now owns 32,112 shares of the company’s stock valued at $161,000 after acquiring an additional 5,936 shares during the period. Finally, Goldman Sachs Group Inc. bought a new stake in TriSalus Life Sciences during the 1st quarter worth approximately $187,000. 2.58% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on TLSI. Canaccord Genuity Group reaffirmed a “buy” rating and set a $11.00 price target on shares of TriSalus Life Sciences in a research note on Friday, March 28th. Roth Mkm reaffirmed a “buy” rating and issued a $11.00 target price on shares of TriSalus Life Sciences in a research note on Friday, January 24th. Finally, Lake Street Capital initiated coverage on shares of TriSalus Life Sciences in a research note on Thursday, February 13th. They issued a “buy” rating and a $10.00 target price on the stock. Seven equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $10.93.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.